 |
|
Antithymocyte Globulin and Cyclosporine for Severe Aplastic Anemia
Association Between Hematologic Response and Long-term Outcome
Stephen Rosenfeld, MD;
Dean Follmann, PhD;
Olga Nunez, RN;
Neal S. Young, MD
JAMA. 2003;289:1130-1135.
Context In most patients, aplastic anemia results from T-cell–mediated immune destruction of bone marrow. Aplastic anemia can be effectively treated by stem cell transplantation or immunosuppression.
Objective To assess long-term outcomes after immunosuppressive therapy.
Design, Setting, and Patients Cohort of 122 patients (31 were  18 years and 91 were >18 years) with severe aplastic anemia, as determined by bone marrow cellularity and blood cell count criteria, were enrolled in a single-arm interventional research protocol from 1991 to 1998 at a federal government research hospital.
Interventions A dose of 40 mg/kg per day of antithymocyte globulin administered for 4 days, 10 to 12 mg/kg per day of cyclosporine for 6 months (adjusted for blood levels), and a short course of corticosteroids (1 mg/d of methylprednisolone for about 2 weeks).
Main Outcome Measures Survival, improvement of pancytopenia and transfusion-independence, relapse, and evolution to other hematologic diseases.
Results Response rates were 60% at 3 months after initiation of treatment, 61% at 6 months, and 58% at 1 year. The blood cell counts of patients who responded no longer satisfied severity criteria and they were transfusion-independent. Overall actuarial survival at 7 years was 55%. Survival was associated with early satisfaction of response criteria (86% vs 40% at 5 years; P<.001) and by blood counts at 3 months (reticulocyte count or platelet count of >50 x 103/µL predicted survival at 5 years of 90% [64/71] vs 42% [12/34] for patients with less robust recovery [P<.001 by log-rank test]). There were no deaths among responders more than 3 years after treatment. Relapse was common, but severe pancytopenia usually did not recur. Relapse did not influence survival. Thirteen patients showed evolution to other hematologic diseases, including monosomy 7.
Conclusions Approximately half of patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine have durable recovery and excellent long-term survival. These outcomes were related to the quality of hematologic recovery.
Author Affiliations: Hematology Branch (Drs Rosenfeld and Young and Ms Nunez) and Office of Biostatistics Research (Dr Follmann), National Heart, Lung, and Blood Institute, Bethesda, Md.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Aplastic Anemia and Immunosuppression
Stephen M. Nagy, Jr and John J. Fisher
JAMA. 2003;290(2):193.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Immunosuppressive treatment for aplastic anemia: are we hitting the ceiling?
Passweg and Tichelli
haematol 2009;94:310-312.
FULL TEXT
Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study
Scheinberg et al.
haematol 2009;94:348-354.
ABSTRACT
| FULL TEXT
The epidemiology of acquired aplastic anemia
Young and Kaufman
haematol 2008;93:489-492.
FULL TEXT
Cellular basis of hematopoiesis and marrow failure syndromes
Cantor and Shimamura
ASH-SAP 2007;2007:23-44.
FULL TEXT
Current concepts in the pathophysiology and treatment of aplastic anemia
Young et al.
Blood 2006;108:2509-2519.
ABSTRACT
| FULL TEXT
Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor
Sloand et al.
Proc. Natl. Acad. Sci. USA 2006;103:14483-14488.
ABSTRACT
| FULL TEXT
New Insights into Paroxysmal Nocturnal Hemoglobinuria
Brodsky
ASH Education Book 2006;2006:24-28.
ABSTRACT
| FULL TEXT
Making Therapeutic Decisions in Adults with Aplastic Anemia
Marsh
ASH Education Book 2006;2006:78-85.
ABSTRACT
| FULL TEXT
Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival
Fuhrer et al.
Blood 2005;106:2102-2104.
ABSTRACT
| FULL TEXT
Systemic lupus erythematosus with refractory hemolytic anemia effectively treated with cyclosporin A: a case report
Wang and Cheng
Lupus 2005;14:483-485.
ABSTRACT
Aplastic Anemia: Management of Adult Patients
Maciejewski and Risitano
ASH Education Book 2005;2005:110-117.
ABSTRACT
| FULL TEXT
Marrow Failure
Bagby et al.
ASH Education Book 2004;2004:318-336.
ABSTRACT
| FULL TEXT
Gene expression profiling in CD34 cells to identify differences between aplastic anemia patients and healthy volunteers
Zeng et al.
Blood 2004;103:325-332.
ABSTRACT
| FULL TEXT
Autoantibodies frequently detected in patients with aplastic anemia
Hirano et al.
Blood 2003;102:4567-4575.
ABSTRACT
| FULL TEXT
Aplastic Anemia and Immunosuppression
Nagy and Fisher
JAMA 2003;290:193-193.
FULL TEXT
|
